A new potential approach to block HIV-1 replication via protein-protein interaction and strand-transfer inhibition by Ferro, Stefania et al.
Bioorganic & Medicinal Chemistry xxx (2014) xxx–xxxContents lists available at ScienceDirect
Bioorganic & Medicinal Chemistry
journal homepage: www.elsevier .com/locate /bmcA new potential approach to block HIV-1 replication via
protein–protein interaction and strand-transfer inhibitionhttp://dx.doi.org/10.1016/j.bmc.2014.02.012
0968-0896/ 2014 Elsevier Ltd. All rights reserved.
⇑ Corresponding author. Tel.: +39 0906766453; fax: +39 0906766402.
E-mail address: sferro@unime.it (S. Ferro).
Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2014), http://dx.doi.org/10.1016/j.bmc.2014.02.012Stefania Ferro a,⇑, Laura De Luca a, Giuseppa Lo Surdo a, Francesca Morreale a, Frauke Christ b,
Zeger Debyser b, Rosaria Gitto a, Alba Chimirri a
aDipartimento di Scienze del Farmaco e dei Prodotti per la Salute, Università di Messina, Viale Annunziata, I-98168 Messina, Italy
bMolecular Virology and Gene Therapy, KU Leuven and IRC KULAK, Kapucijnenvoer 33, B-3000 Leuven, Flanders, Belgium
a r t i c l e i n f o a b s t r a c tArticle history:
Received 22 October 2013
Revised 28 January 2014
Accepted 10 February 2014
Available online xxxx
Keywords:
Protein–protein interaction
Strand-transfer
Docking studies
SynthesisTherapeutic treatment of AIDS is recently characterized by a crescent effort towards the identiﬁcation of
multiple ligands able to target different steps of HIV-1 life cycle. Taking into consideration our previously
obtained SAR information and combining some important chemical structural features we report herein
the synthesis of novel benzyl-indole derivatives as anti-HIV agents. Through this work we identiﬁed new
dual target small molecules able to inhibit both IN-LEDGF/p75 interaction and the IN strand-transfer step
considered as two crucial phases of viral life cycle.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Although three decades of research against the human immu-
nodeﬁciency virus type 1 (HIV-1), acquired immunodeﬁciency syn-
drome (AIDS) pandemic and AIDS-related diseases remain among
the leading causes of deaths worldwide. The latest UNAIDS report
for the end of 2012 indicates that over 34 million individuals are
living with HIV and 2.5 million new infections occur every years.1
The current combination antiretroviral therapy (cART), based
on advances in the understanding of the viral life cycle, has
resulted in major advances in the longevity and quality of life for
infected patients, improving the clinical outcome of the disease
and transforming AIDS from a rapid and lethal infection into a
manageable chronic condition.2–4
However, the era of cART is not without problems: the emer-
gence of drug-resistant viral strains, persistent toxicities, the poor
ability of patients to adhere to the prescribed therapy and costs
make desirable to identify additional medications targeting simul-
taneously different steps in the HIV-1 viral life cycle.5,6
It has been reported that HIV-1 requires three main steps for
effective viral replication: reverse transcription of the RNA viral
genome into viral cDNA by viral reverse transcriptase (RT); inte-
gration of viral cDNA into the host cell genome using viral integr-
ase (IN); and, ﬁnally, cleavage of newly synthesized viralpolypeptides by viral protease into single viral proteins during
new virion assembly.7
Throughout the years, all these steps were approached, and spe-
ciﬁc inhibitory molecules were developed and licensed to block
viral enzymes, thus preventing disease progression. Only in the last
decade the viral IN has emerged as a primary alternative target to
block HIV-1 replication. This enzyme is critical for retroviral
replication and is particularly interesting because no homolog is
present in human cells. IN performs three functions that lead to
viral integration into the host cell genome. The ﬁrst is site-speciﬁc
endonucleolytic cleavage of the 30-ends of the viral DNA (30P).
Secondly, it participates in the assembly of the pre-integration
complex (PIC) on the ends of the viral DNA, which migrates into
the host nucleus. Lastly, in the strand-transfer step (ST) IN cataly-
ses the insertion of the viral DNA into host chromosomal DNA.
Figure 1 are shows some ﬁrst generation integrase strand-trans-
fer inhibitors (INSTIs).
At the end of 2007 the ﬁrst INSTI, raltegravir, clinically effective
against viruses resistant to other classes of antiretroviral agents,
was approved for the clinical use by the US Food and Drug Admin-
istration (FDA) and European Medicines Agency (EMA).8
Neverthless, raltegravir has a relatively low genetic barrier to
resistance9,10 and, in contrast to prior predictions based on
in vitro experiments, resistance evolves readily in the clinic.11
Elvitegravir12,13 is another ﬁrst generation IN inhibitor, charac-
terized by virologic activity comparable with raltegravir, and
administered once daily combined with a pharmacological booster.
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Figure 1. First and second generation of integrase strand-transfer inibitors (INSTIs).
2 S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxxUnfortunately, it is also cross-resistant with raltegravir and there-
fore it is no treatment option for patients failing on INSTIs.
The need to overcome these problems has driven the develop-
ment of a second generation of INSTIs such as dolutegravir
(Fig. 1) approved on August 2013.14
As the ﬁrst-generation integrase inhibitors, dolutegravir blocks
the strand-transfer step of integration of the viral cDNA into the
host genome. It displays superior characteristics to raltegravir,
but partially it shares the resistance pathways.15,16
Therefore, alternative strategies and new targets, such as the
design of inhibitors of the interactions of IN with essential cellular
co-factors of integration, need to be identiﬁed to combat the grow-
ing AIDS pandemic.
The ubiquitous lens epithelium growth factor LEDGF/p75 is a
cellular cofactor of IN HIV-1, acting to tether the provirus to the
cellular genome and playing a crucial role in the transcriptional
regulation. It was demonstrated that IN-LEDGF/p75 interaction
inhibitors (LEDGINs) are active against a wide range of INSTIs-
resistant mutants and exhibit additive or synergistic activity when
combined with INSTIs.17
Our previous studies led to the discovery of small molecule
protein-protein interaction inhibitors (SMPPIIs), belonging to theN
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Figure 2. Chemical structure of CHIBA-3053 and CHI-1043 and their m
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tween IN and LEDGF/p75,18,19 and CHIBA-3053 was the most active
compound (Fig. 2)19 of the series.
More recently, we found that one of the most promising indoles
developed as INSTIs (CHI-1043) showed also to be active against
the IN-LEDGF/p75 interaction at micromolar concentration20
(Fig. 2).
As a continuation of our research studies in this ﬁeld we de-
signed novel small molecules, containing the same scaffold of CHI-
BA and CHI analogues as potential inhibitors for the catalytic site of
IN as well as the LEDGF/p75–IN interaction. Herein, we report the
synthesis and the biological activity of this series of compounds, in
which further exploration with hydrophobic groups at N1 was per-
formed. The most active derivatives were subjected to molecular
docking studies in order to analyse the binding mode of these
new dual inhibitors.
2. Results and discussion
2.1. Design of new analogues
LEDGF/p75 is a cellular cofactor of HIV-1 integrase that inter-
acts with the enzyme via its C-terminal domain, also known as
the IN binding domain (LEDGFIBD) and promotes viral integration
by tethering the preintegration complex to the chromatin.
Several literature data support the notion that the LEDGF/p75–
IN interaction is a promising target for anti-HIV drug develop-
ment.21–24 Searching for HIV-1 inhibitors targeting protein–protein
interactions in our previous studies we reported the discovery of a
series of benzylindole derivatives able to block the IN-LEDGF/p75
interaction. The most potent compound was the 4-[1-(3,5-dimeth-
ylbenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic
acid (CHIBA-3053), which showed an IC50 value of 3.5 lM (Fig. 2).
Moreover, considering that targeting different stages in the
integration phase represents a new attractive approach for future
inhibitor design,25–28 we focused our efforts towards the discovery
of new molecules with potential dual site binding ability.
Our goal was to identify small molecules able to inhibit both the
IN strand-transfer step and IN-LEDGF/p75 interaction.Protein-Protein Interacon Inhibitor
Strand Transfer Inhibitor and
Protein-Protein Interacon Inhibitor
ajor structural determinants for PPI and ST inhibition, respectively.
014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
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(Fig. 2), considered the most promising compound of our INSTIs
(IC50 = 0.14 lM; EC50 = 0.59 lM; SI = 70), proved to be able to inhi-
bit the IN-LEDGF/p75 interaction with an IC50 value of 36.16 lM,
representing an interesting prototype of dual target agent.20
So, encouraged by these results and taking into consideration
the information already obtained by our previous researches we
decided to synthesize a new series of dual small molecules, com-
bining the chemical structural features of CHIBA and CHI analogues
(Fig. 2).
2.2. Chemistry
Scheme 1 illustrates the general synthetic route for the prepara-
tion of a new series of 1H-benzyl indole derivatives (13–18 a–f). By
standard synthetic chemistry,19,29–31 the indole scaffold was easily
equipped with a functional chain at the C3 position and the intro-
duction of the benzyl moiety at N1, thus probing several substitu-
tions for rapid exploration of the SAR proﬁle. The C3 position of the
indole nucleus was functionalized through the Vilsmeier–Haack
reaction (4–6). Then various aryl groups were attached to the N1
atom using dry sodium hydride and the suitable benzyl bromide,
and the obtained intermediates 7–9 a–f were reacted with diethyl
oxalate to provide the key ethyl ester precursors (10–12 a–f) of de-
sired compounds. Finally, the esters were hydrolyzed in basic med-
ium to give the ﬁnal diketo acids (13–15 a–f), or converted into the
corresponding hydroxyl-furanones derivatives (16–18 a–f) by
treatment with an aqueous solution of formaldehyde.N
H
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Scheme 1. Synthetic route of benzyl-indole derivatives. Reagents and conditions: (i) POC
at continuous temperature (50 C), 100 Watt; (iii) diethyl oxalate, dry CH3ONa, THF, two
(50 C), 250 Watt; (iv) 2 N NaOH, MeOH, RT, 1.5 h; (v) CH2O, Et2O/H2O, RT, 2 h.
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We tested all the new synthesized compounds in the Alpha-
Screen assay to evaluate their inhibitory effects on the LEDGF/
p75–IN interaction. The biological screening has been carried out
on the diketo acids 13–15 a–f as well as on the hydroxyl-furanone
16–18 a–f derivatives.
The obtained results are shown in Tables 1 and 2.
Among the compounds belonging to the diketo acid series
(Table 1) the best results were displayed for compounds 13b, 13c
and 14b (IC50 = 22.9, 9.99 and 9.76 lM). All of them were charac-
terized by the presence of a halogen atom (Cl for 13b and 13c, F
for 14b) at 5 position of the indole nucleus and of some bulky
hydrophobic substituents on the benzyl moiety: 4-triﬂuoromethyl
(13b and 14b) and 4-tert-butyl (13c) group, thus conﬁrming our
already reported studies.19
In fact, we have previously identiﬁed a new hydrophobic region
in IBD binding site and demonstrated the importance of lipophilic
chemical features for IN-LEDGF inhibition. Better biological results
in the Alpha screen assay were obtained when the diketo acid
chain has been turned into the hydroxyl-furanone cycle (Table 2).
For this series (16–18 a–f) the synthesized compounds generally
showed PPI inhibition at micromolar concentration thus highlight-
ing that the structural modiﬁcation of diketoacid motif in hydro-
xyl-furanone is well tolerated for the inhibition of the IN-LEDGF
interaction.
Particularly compound 17f, in which the presence of ﬂuorine
atom on the indole nucleus was associated to the introduction ofN
O OH
COOEt
N
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iv
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l3, CH3CON(CH3)2, RT, 12 h; (ii) benzyl bromide or chloride, NaH, DMF, mw: 10 min
separate steps under the same conditions mw: 2 min, at continuous temperature
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Table 4
Inhibition of HIV-1 integrase strand-transfer activity of diketo acid derivatives
No. Strand-transfera (lM)
13b 0.26 ± 0.01
14b 1.55 ± 0.24
14f 2.51 ± 0.56
15e 1.09 ± 0.15
15f 0.42 ± 0.15
CHI-1043 0.14 ± 0.11
a Concentration required to inhibit by 50% the in vitro integrase activity assays as
IC50 (lM).
Table 1
Inhibition of IN–LEDGF/p75 interaction of diketo acid derivatives (13–15 a–f)
No. %a IC50b (lM) No. % a IC50b (lM)
13a 31 NDd 14d NA NDd
13b 80 32.9 ± 3.5 14e 26 NDd
13c 88 10.0 ± 3.4 14f 71 15.2 ± 1.6
13d 80 3.8 ± 0.3 15a 59 >100
13e NAc NDd 15b32 40 NDd
13f 59 >100 15c 65 91.7 ± 6.2
14a 72 8.1 ± 2.9 15d 33 NDd
14b 77 17.8 ± 7.4 15e 89 53.9 ± 4.9
14c 33 ND 15f 72 33.1 ± 0.1
CHIBA-3053 3.5
CHI-1043 36.16
a % Inhibition at 100 lM.
b IC50: concentration required to inhibit the HIV-1 IN–LEDGF/p75 interaction by
50%. The average of two IC50 determinations and the error is shown.
c NA: not active.
d ND: not detected.
Table 2
Inhibition of IN–LEDGF/p75 interaction of hydroxyl-furanones derivatives (16–18 a–
f)
No. %a IC50b (lM) No. %a IC50b (lM)
16a 80 21.8 ± 2.9 17d 37 NDc
16b 92 12.3 ± 1.1 17e 73 20.3 ± 1.8
16c 83 52.5 ± 1.8 17f 81 5.6 ± 2.5
16d 86 21.5 ± 0.8 18a 51 NDc
16e 96 23.1 ± 0.5 18b 65 52.2 ± 9.5
16f 85 23.6 ± 2.2 18c 93 17.1 ± 2.2
17a 89 15.8 ± 4.4 18d 61 39.5 ± 6.9
17b 65 12.2 ± 6.5 18e 66 NDc
17c 96 36.2 ± 3.4 18f 82 33.2 ± 1.9
CHIBA-3053 3.50
CHI-1043 36.16
a % Inhibition at 100 lM.
b IC50: concentration required to inhibit the HIV-1 IN–LEDGF/p75 interaction by
50%. The average of two IC50 determinations and the error is shown.
c ND: not detected.
4 S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxxtrimethyl-substitution on the benzyl moiety, showed higher
potency (IC50 = 2.44) than our lead compound CHIBA-3053
(IC50 = 3.50).
In general, by comparison of data reported in Tables 1 and 2 the
diketo acid derivatives 13–15 a–f are less active than the corre-
sponding hydroxyl-furanones 16–18 a–f.
2.4. In vitro anti-HIV and drug susceptibility assays
All the synthesized derivatives were also tested in MT-4/MTT-
assay as anti-HIV agents and Table 3 shows the results for only
active compounds.
The selected compounds proved to be active at micromolar
concentration; generally the diketoacid derivatives (13–15) dem-Table 3
Antiviral activities of diketo acid derivatives (13–15 a–f) and hydroxyl-furanones (16–18
No. EC50a (lM) CC50b (lM) SIc
13b 5.09 ± 1.22 23 ± 3.54 5
13e 56.15 ± 2.80 >125 >2
14b 7.83 ± 1.56 15 ± 1.75 2
14f 5.14 ± 2.9 104 ± 53 21
15e 2.24 ± 0.78 51 ± 4.68 23
15f 3.23 ± 0.64 23.5 ± 2.86 8
a EC50: effective concentration required to reduce HIV-1-induced cytopathic effect by
b CC50: cytotoxic concentration to reduce MT-4 cell viability by 50%.
c SI: ratio CC50/EC50.
Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2onstrated better anti-HIV activity than of the closed analogues
(16–18).
The better anti-HIV activity of diketoacids series respect to the
hydroxyl-furanones (e.g. 17f) can be explained considering the sec-
ond series of compounds as pro-drugs of the open chain DKA
derivatives.32
2.5. Integrase strand-transfer inhibition
On the basis of the above reported results and taking into ac-
count that one of our objectives was to identify small molecules
able to simultaneously inhibit two different integration processes,
we focused our attention only on those diketoacids active as anti-
HIV agents for evaluating their potential activity also on the
strand-transfer step of IN HIV-1 integration. Thus derivatives
13b, 14b, 14f, 15e and 15f (Table 3) were selected and tested in
in vitro integration assays. The obtained results are reported in
Table 4.
As expected, all ﬁve derivatives showed relevant activity in the
strand-transfer step at very low micromolar range. Indeed our pre-
vious SAR ﬁndings and molecular modeling studies on benzylin-
dole diketo acids had suggested that the diketo acid portion
furnishes the triad oxygen lone-pairs to serve as chelating center
of the two divalent metals and that the 4-substituted benzyl group
provided the appropriate spatial relationship for the aromatic moi-
ety required for the inhibition of the integration strand-transfer
event. In particular compound 14b has an IC50 in the lowmicromo-
lar range for both IN-LEDGF/p75 interaction inhibition and strand
transfer step.
2.6. Docking studies
Using Gold software and according to our previously applied
protocols20,33,34 we carried out docking experiments of the most
active compounds, in order to clarify their interaction with the
LEDGF binding site and the catalytic site on IN. Docking results
for the most promising dual inhibitor 14b are shown in Figure 3.
As regards the docking pose of 14b into the LEDGF binding site
(Fig. 3A), the key interactions include hydrogen bonds between thea–f)
No. EC50a (lM) CC50b (lM) SIc
16c 23.45 ± 2.45 53 ± 7 2
16e 16.93 ± 3.9 53.5 ± 1.5 3
16f 19.83 ± 1.26 40.5 ± 4.5 2
17f 48.96 ± 6.8 107 ± 12 2
CHIBA-3053 4.63 44 10
CHI-1043 0.59 41.1 70
50% in MT-4 cells.
014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
Figure 3. Docking of 14b (green) into (A) LEDGF/p75 binding pocket on IN core domain (PDB code 2B4J) and (B) PFV IN active site in its bound state with DNA (PDB code
3OYA). The divalent metal ions are shown as gray spheres, while the viral DNA is depicted in pink. This ﬁgure was produced with PyMol (DeLano Scientiﬁc LLC).
S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxx 5diketo acid moiety and the main chain nitrogens of residues
Glu170 and His171 as well as the side chain of residues Thr174
and Gln95. The N-benzyl substituent displays hydrophobic con-
tacts for the crucial Trp131, while the fused benzene ring of the in-
dole nucleus projects into the IN hydrophobic pocket with the
ﬂuorine atom forming interactions with residue Leu102 and
Ala129 side chains.
The binding mode at the catalytic site during the strand-trans-
fer step was predicted by docking 14b on the structure of integrase
from PFV in complex with DNA and two Mg ions as previously
reported for CHI-1043 (Fig. 3B). The diketo acid moiety represents
the common metal-coordinating pharmacophore of INSTIs, and the
5-F indole group contacts Pro214, while the p-substituted benzyl
moiety (that represents the second conserved feature in the INSTIs)
interacts with viral DNA bases and residue Gln215.
In summary docking studies provide insights into the binding
mode of 14b to form the relevant key interactions in both sites
on IN.
3. Conclusion
In conclusion we obtained novel anti-HIV agents some of which
are dual inhibitors of the integration process acting both in the IN
strand-transfer step and by disrupting the protein–protein interac-
tion between IN and its cofactor LEDGF/p75. Our approach was
based on molecular modiﬁcation of the indole b-diketo acid scaf-
fold present in some inhibitors of IN–LEDGF interaction and de-
scribed as an important pharmacophoric feature for INSTIs.
4. Experimental section
4.1. Chemistry
All commercially available reagents and solvents were used
without any further puriﬁcation. The microwave-assisted reactions
were carried out in a CEM Focused Microwave Synthesis System,
Model Discover, working at the power necessary for reﬂuxing un-
der atmospheric conditions. Melting points were determined on a
BUCHI Melting Point B-545 apparatus and are uncorrected. Ele-
mental analyses (C, H and N) were carried out on a Carlo Erba Mod-
el 1106 Elemental Analyzer and the results are within ±0.4% of the
theoretical values. Merck silica gel 60 F254 plates were used for
analytical TLC; column chromatography was performed on Merck
silica gel 60 (230–400 mesh) and Flash Chromatography (FC) on
a Biotage SP1 EXP. 1H NMR spectra were recorded in CDCl3 with
TMS as internal standard or [D6]DMSO on a Varian Gemini-300Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2spectrometer. Chemical shifts were expressed in d (ppm) and cou-
pling constants (J) in hertz (Hz). All the exchangeable protons were
conﬁrmed by addition of D2O.
4.2. Synthesis of 3-acetyl-1H-indoles (4–6)
Synthesis of intermediates 4-6 was carried out following the
previously reported procedure. Phosphoryl chloride (0.92 ml,
10 mmol) was added to ice cold dimethylacetamide (2.79 ml,
30 mmol) under stirring and cooling in ice. The suitable starting
material (1–3) (1 mmol) was added and the reaction mixture was
stirred at room temperature for 12 h, then poured over ice and
basiﬁed with 4 N aqueous sodium hydroxide solution. The mixture
was extracted with ethyl acetate and dried over Na2SO4. After re-
moval of the solvent under reduced pressure, the residue was pow-
dered by treatment with diethyl ether and recrystallized from
dichloromethane.
4.2.1. 3-Acetyl-5-chloro-1H-indole (4)
Spectral data are in accordance with the literature.32,35
4.2.2. 3-Acetyl-5-ﬂuoro-1H-indole (5)
Mp 202–204 C, yield 46%; 1H NMR (DMSO-d6): 2.43 (s, 3H,
CH3), 7.05–7.84 (m, 3H, ArH), 8.36 (s, 1H, ArH), 12.02 (br s, 1H,
NH). Anal. Calcd for C10H8FNO: C, 67.79; H, 4.55; N, 7.91. Found:
C, 67.94; H, 4.31; N, 7.72.
4.2.3. 3-Acetyl-5-methoxy-1H-indole (6)
Spectral data are in accordance with the literature.32,35
4.3. General procedure for the synthesis of 3-acetyl-1-benzyl-
1H-indoles (7–9 a–f)
Using the synthetic procedure previously reported by us18–
20,29,36 3-acetyl-1H-indole derivatives 4–6 were dissolved in DMF
(2 ml) at 0 C and dry sodium hydride (120 mg, 5 mmol) was
added. After stirring for 2 min, the suitable benzyl bromide or chlo-
ride (1.5 mmol) was added in several portions. The resulting solu-
tion was placed in a cylindrical quartz tube (diam. 2 cm), stirred
and irradiated in a microwave oven at 100W and at continuous
temperature (50 C) for 10 min. A saturated NaHCO3 solution was
added. The reaction mixture was extracted with ethyl acetate
(10 ml  3) and dried over Na2SO4. After removal of the solvent un-
der reduced pressure, the crude mixture was crystallized from
diethyl ether or puriﬁed by ﬂash chromatography using a mixture
of cyclohexane/ethylacetate (60:40) as eluent.014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
6 S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxx4.3.1. 3-Acetyl-1-(4-phenylbenzyl)-5-chloro-1H-indole (7a)
Mp 154–56 C, yield 90%; 1H NMR (d) (CDCl3): 2.52 (s, 3H, CH3),
5.38 (s, 2H, CH2), 7.20–7.24 (m, 3H, ArH), 7.36–7.47 (m, 4H, ArH),
7.55–7.59 (m, 4H, ArH), 7.80 (s, 1H, ArH), 8.43 (s, 1H, ArH). Anal.
Calcd for C23H18ClNO: C: 76.77; H: 5.04; N: 3.89. Found: C:
76.45; H: 5.23; N: 3.68.
4.3.2. 3-Acetyl-1-(4-triﬂuoromethylbenzyl)-5-chloro-1H-indole
(7b)
Mp 163–165 C, yield 50%; 1H NMR (CDCl3): 2.52 (s, 3H, CH3),
5.41 (s, 2H, CH2), 7.12 (d, J = 9.1, 1H, ArH), 7.21–7.26 (m, 3H,
ArH), 7.60 (d, J = 8.2, 2H, ArH), 7.77 (s, 1H, ArH), 8.43 (s, 1H,
ArH). Anal. Calcd for C18H13ClF3NO: C: 61.46; H: 3.73; N: 3.98.
Found: C: 61.72; H: 3.89; N: 4.03.
4.3.3. 3-Acetyl-1-(4-tert-butylbenzyl)-5-chloro-1H-indole (7c)
Mp 158–160 C, yield 44%; 1H NMR (CDCl3): 1.30 (s, 9H, CH3),
2.50 (s, 3H, CH3), 5.30 (s, 2H, CH2), 7.10 (d, J = 8.5, 2H, ArH), 7.22
(s, 1H, ArH), 7.36 (d, J = 8.5, 2H, ArH), 7.75 (s, 1H, ArH), 8.40 (s,
1H, ArH). Anal. Calcd for C21H22ClNO: C: 74.22; H: 6.52; N: 4.12.
Found: C: 74.34; H: 6.36; N: 4.31.
4.3.4. 3-Acetyl-1-(2,4-bis-triﬂuoromethylbenzyl)-5-chloro-1H-
indole (7d)
Mp 163–165 C, yield 35%; 1H NMR (CDCl3): 2.55 (s, 3H, CH3),
5.63 (s, 2H, CH2), 6.71 (d, J = 7.6, 1H, ArH), 7.03 (d, J = 8.8, 1H,
ArH), 7.23 (d, J = 8.8, 1H, ArH), 7.64 (d, J = 7.6, 1H, ArH), 7.79 (s,
1H, ArH), 8.02 (s, 1H, ArH), 8.45 (s, 1H, ArH). Anal. Calcd for C19H12-
ClF6NO: C: 54.37; H: 2.88; N: 3.34. Found: C: 54.55; H: 3.09; N:
3.61.
4.3.5. 3-Acetyl-1-(3,5-dimethylbenzyl)-5-chloro-1H-indole (7e)
Mp 136–138 C, yield 47%; 1H NMR (CDCl3): 2.27 (s, 3H, CH3),
2.50 (s, 3H, CH3), 5.24 (s, 2H, CH2), 6.75 (s, 2H, ArH), 6.95 (s, 1H,
ArH), 7.19–7.22 (m, 2H, ArH), 7.74 (s, 1H, ArH), 8.40 (s, 1H, ArH).
Anal. Calcd for C19H18ClNO: C: 73.19; H: 5.82; N: 4.49. Found: C:
73.34; H: 5.71; N: 4.56.
4.3.6. 3-Acetyl-1-(2,4,6-trimethylbenzyl)-5-chloro-1H-indole
(7f)
Mp 193–195 C, yield 67%; 1H NMR (CDCl3): 2.22 (s, 6H, CH3),
2.35 (s, 3H, CH3), 2.36 (s, 3H, CH3), 5.20 (s, 2H, CH2), 6.87 (s, 1H,
ArH), 6.99 (s, 2H, ArH), 7.18 (s, 1H, ArH), 7.30 (d, J = 8.8, 1H,
ArH), 7.43 (d, J = 8.8, 1H, ArH). Anal. Calcd for C20H20ClNO: C:
73.72; H: 6.19; N: 4.30. Found: C: 73.59; H: 6.33; N: 4.48.
4.3.7. 3-Acetyl-1-(4-phenylbenzyl)-5-ﬂuoro-1H-indole (8a)
Mp 81–83 C, yield 48%; 1H NMR (CDCl3): 2.52 (s, 3H, CH3), 5.39
(s, 2H, CH2), 7.02 (t, J = 9, 1H, ArH), 7.21–7.25 (m, 3H, ArH), 7.37 (d,
J = 6.9, 1H, ArH), 7.44 (t, J = 8, 2H, ArH), 7.55–7.62 (m, 4H, ArH),
7.82 (s, 1H, ArH), 8.10 (d, J = 9.6, 1H, ArH). Anal. Calcd for C23H18-
FNO: C: 80.45; H: 5.28: N, 4.08. Found: C: 80.21; H: 5.45; N: 4.24.
4.3.8. 3-Acetyl-1-(4-triﬂuoromethylbenzyl)-5-ﬂuoro-1H-indole
(8b)
Mp 185–187 C, yield 62%; 1H NMR (CDCl3): 2.53 (s, 3H, CH3),
5.42 (s, 2H, CH2), 7.01 (t, J = 9, 1H, ArH), 7.13 (d, J = 9, 1H, ArH),
7.23 (d, J = 7.9, 2H, ArH), 7.60 (d, J = 8.2, 2H, ArH), 7.80 (s, 1H,
ArH), 8.10 (d, J = 9.5, 1H, ArH). Anal. Calcd for C18H13F4NO: C:
64.48; H: 3.91; N: 4.18. Found: C: 64.32; H: 3.74; N: 4.29.
4.3.9. 3-Acetyl-1-(4-tert-butylbenzyl)-5-ﬂuoro-1H-indole (8c)
Mp 132–134 C, yield 50%; 1H NMR (CDCl3): 1.32 (s, 9H, CH3),
2.52 (s, 3H, CH3), 5.33 (s, 2H, CH2), 7.02 (t, J = 8.8, 1H, ArH), 7.11
(d, J = 8.8, 2H, ArH), 7.23–7.28 (m, 1H, ArH), 7.39 (d, J = 8.8, 2H,
ArH), 7.79 (s, 1H, ArH), 8.09 (d, J = 9.9, 1H, ArH). Anal. Calcd for C21-Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2H22FNO: C: 77.99; H: 6.86; N: 4.33. Found: C: 78.13; H: 6.99; N:
4.22.
4.3.10. 3-Acetyl-1-(2,4-bis-triﬂuoromethylbenzyl)-5-ﬂuoro-1H-
indole (8d)
Mp 144–146 C, yield 35%; 1H NMR (CDCl3): 2.55 (s, 3H, CH3),
5.63 (s, 2H, CH2), 6.73 (d, J = 8.2, 1H, ArH), 7.03 (d, J = 8.2, 2H,
ArH), 7.65 (d, J = 8.2, 1H, ArH), 7.82 (s, 1H, ArH), 8.02 (s, 1H,
ArH), 8.13 (d, J = 9.2, 1H, ArH). Anal. Calcd for C19H12F7NO: C:
58.92; H: 3.12; N: 3.62. Found: C: 59.21; H: 3.45; N: 3.96.
4.3.11. 3-Acetyl-1-(3,5-dimethylbenzyl)-5-ﬂuoro-1H-indole (8e)
Mp 146–148 C, yield 57%; 1H NMR (CDCl3): 2.28 (s, 6H, CH3),
2.51 (s, 3H, CH3), 5.25 (s, 2H, CH2), 6.76 (s, 2H, ArH), 6.96–7.02
(m, 2H, ArH), 7.20–7.24 (m, 1H, ArH), 7.76 (s, 1H, ArH), 8.08 (d,
J = 7.4, 1H, ArH). Anal. Calcd for C19H18FNO: C: 77.27; H: 6.14; N:
4.74. Found: C: 77.39; H: 6.28; N: 4.81.
4.3.12. 3-Acetyl-1-(2,4,6-trimethylbenzyl)-5-ﬂuoro-1H-indole
(8f)
Mp 135–137 C, yield 42%; 1H NMR (CDCl3): 2.23 (s, 6H, CH3),
2.36 (s, 6H, CH3), 5.21 (s, 2H, CH2), 6.88 (s, 1H, ArH), 6.99 (s, 1H,
ArH), 7.10 (t, J = 8.8, 1H, ArH), 7.19 (s, 1H, ArH), 7.43 (d, J = 8.8,
1H, ArH), 8.07 (d, J = 9.6, 1H, ArH). Anal. Calcd for C20H20FNO: C:
77.64; H: 6.52; N: 4.53. Found: C: 77.87; H: 6.68; N: 4.31.
4.3.13. 3-Acetyl-1-(4-phenylbenzyl)-5-methoxy-1H-indole (9a)
Mp 154–156 C, yield 90%; 1H NMR (CDCl3): 2.52 (s, 3H, CH3),
3.91 (s, 3H, OCH3), 5.37 (s, 2H, CH2), 6.91 (d, J = 8.8, 1H, ArH),
7.20–7.24 (m, 3H, ArH), 7.37 (d, J = 7.2, 1H, ArH) 7.44 (t, J = 8.8,
2H, ArH), 7.55–7.58 (m, 4H, ArH), 7.76 (s, 1H, ArH), 7.94 (s, 1H,
ArH). Anal. Calcd for C24H21NO2: C: 81.10; H: 5.96; N: 3.94. Found:
C: 81.34; H, 5.72; N, 4.09.
4.3.14. 3-Acetyl-1-(4-triﬂuoromethylbenzyl)-5-methoxy-1H-
indole (9b)
Mp 122–124 C, yield 70%; 1H NMR (CDCl3): 2.53 (s, 3H, CH3),
3.90 (s, 3H, OCH3), 5.40 (s, 2H, CH2), 6.90 (d, J = 8.8, 1H, ArH),
7.09 (d, J = 8.8, 1H, ArH), 7.23 (d, J = 8, 2H, ArH), 7.60 (d, J = 8.2,
2H, ArH), 7.73 (s, 1H, ArH), 7.93 (s, 1H, ArH). Anal. Calcd for C19H16-
F3NO2: C: 65.70; H: 4.64; N: 4.03. Found: C: 65.87; H: 4.48; N: 4.21.
4.3.15. 3-Acetyl-1-(4-tert-butylbenzyl)-5-methoxy-1H-indole
(9c)
Mp 149–151 C, yield 73%; 1H NMR (CDCl3): 1.29 (s, 9H, CH3),
2.68 (s, 3H, CH3), 3.97 (s, 3H, OCH3), 5.25 (s, 2H, CH2), 6.69 (d,
J = 7.9, 1H, ArH), 6.96 (d, J = 7.9, 1H, ArH), 7.09 (d, J = 8.5, 2H,
ArH), 7.17 (d, J = 7.9, 1H, ArH), 7.34 (d, J = 8.5, 2H, ArH), 7.72 (s,
1H, ArH). Anal. Calcd for C22H25NO2: C: 78.77; H: 7.51; N: 4.18.
Found: C: 78.95; H: 7.74; N: 4.51.
4.3.16. 3-Acetyl-1-(2,4-bis-triﬂuoromethylbenzyl)-5-methoxy-
1H-indole (9d)
Mp 158–160 C, yield 37%; 1H NMR (DMSO-d6): 2.49 (s, 3H,
CH3), 3.80 (s, 3H, OCH3), 5.80 (s, 2H, CH2), 6.80 (d, J = 8.4, 1H,
ArH), 6.92 (s, 2H, ArH), 7.25 (d, J = 8.8, 2H, ArH), 7.79 (s, 1H,
ArH), 7.95 (d, J = 8.4, 1H, ArH), 8.13 (s, 1H, ArH), 8.86 (s, 1H,
ArH). Anal. Calcd for C20H15F6NO2: C: 57.84; H: 3.64; N: 3.37.
Found: C: 57.70; H: 3.81; N: 3.52.
4.3.17. 3-Acetyl-1-(3,5-dimethylbenzyl)-5-methoxy-1H-indole
(9e)
Mp 130–132 C, yield 59%; 1H NMR (CDCl3): 2.27 (s, 6H, CH3),
2.50 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 5.22 (s, 2H, CH2), 6.77 (s,
2H, ArH), 6.91 (t, J = 8.8, 2H, ArH), 7.19 (d, J = 8.8, 1H, ArH), 7.69014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
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H: 6.89; N: 4.56. Found: C: 78.36; H: 6.72; N: 4.68.
4.3.18. 3-Acetyl-1-(2,4,6-trimethylbenzyl)-5-methoxy-1H-
indole (9f)
Mp 150–152 C, yield 28%; 1H NMR (CDCl3): 2.23 (s, 6H, CH3),
2.35 (s, 6H, CH3), 3.91 (s, 3H, OCH3), 5.19 (s, 2H, CH2), 6.97–7.01
(m, 2H, ArH), 7.12 (s, 1H, ArH), 7.40 (d, J = 8.5, 2H, ArH), 7.92 (s,
1H, ArH). Anal. Calcd for C21H23NO2: C: 78.47; H: 7.21; N: 4.36.
Found: C: 78.69; H: 7.04; N: 4.54.
4.4. General procedure for the synthesis of ethyl 4-[1-benzyl-
1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoates (10–12 a–f)
Intermediates 10–12 a–f were obtained adopting the synthetic
procedure previously reported by us.18,19,31,32 A mixture of suitable
3-acetyl-1-benzyl-1H-indole (7–9 a–f) (1 mmol) diethyl oxalate
(219 mg, 1.5 mmol) and a catalytic amount of NaOCH3 was sus-
pended in anhydrous THF (2 ml). The reaction mixture was placed
in a cylindrical quartz tube (diam. 2 cm), stirred and irradiated at
continuous temperature in a microwave oven for two successive
time intervals under the same conditions (250 Watt, 2 min,
50 C). The solvent was concentrated under reduced pressure and
collected yellow solid was crystallized from ethanol and diethyl
ether (1:4).
4.4.1. Ethyl 4-[1-(4-phenylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoate (10a)
Mp 198–200 C, yield 95%; 1H NMR (DMSO-d6): 1.24 (t, J = 7.3,
3H, CH3), 4.12 (q, J = 7.3, 2H, CH2), 5.50 (s, 2H, CH2), 6.21 (br s,
1H, OH), 7.12 (d, J = 9, 1H, ArH), 7.31–7.45 (m, 6H, 5ArH and CH),
7.52 (d, J = 7.6, 1H, ArH), 7.58–7.61 (m, 4H, ArH), 8.25 (s, 1H,
ArH), 8.36 (s, 1H, ArH). (Anal. Calcd for C27H22ClNO4: C: 70.51; H:
4.82; N: 3.05. Found: C: 70.12; H: 4.99; N: 3.24.
4.4.2. Ethyl 4-{1-[4-(triﬂuoromethyl)benzyl]-5-chloro-1H-
indol-3-yl}-2-hydroxy-4-oxobut-2-enoate (10b)
Mp 170–172 C, yield 75%; 1H NMR (DMSO-d6): 1.24 (t, J = 7.3,
3H, CH3), 3.94 (q, J = 7.3, 2H, CH2), 5.59 (s, 2H, CH2), 6.35 (s, 1H,
OH), 7.14 (d, J = 8, 1H, ArH), 7.42 (d, J = 8, 2H, ArH and CH), 7.47
(d, J = 8.9, 2H, ArH), 7.68 (d, J = 8, 2H, ArH), 8.38 (s, 1H, ArH), 8.43
(s, 1H, ArH). Anal. Calcd for C22H17ClF3NO4: C: 58.48; H: 3.79; N:
3.10. Found: C: 58.61; H: 4.03; N: 3.17.
4.4.3. Ethyl 4-[1-(4-tert-butylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoate (10c)
Mp 280 C dec, yield 85%; 1H NMR (DMSO-d6): 1.20 (s, 9H, CH3),
1.24 (t, J = 6.9, 3H, CH3), 4.13 (d, J = 7.2, 2H, CH2), 5.41 (s, 2H, CH2),
6.16 (s, 1H, ArH), 7.11–7.22 (m, 3H, 2ArH and CH), 7.33 (d, J = 7.7,
2H, ArH), 7.50 (d, J = 8.8, 1H, ArH), 8.17 (s, 1H, ArH), 8.43 (s, 1H,
ArH), 8.53 (s, 1H, ArH). Anal. Calcd for C25H26ClNO4: C: 68.25; H:
5.96; N: 3.18. Found: C: 68.34; H: 6.01; N: 3.25.
4.4.4. Ethyl 4-{1-[2,4-bis(triﬂuoromethyl)benzyl]-5-chloro-1H-
indol-3-yl}-2-hydroxy-4-oxobut-2-enoate (10d)
Mp 223–225 C, yield 68%; 1H NMR (DMSO-d6): 1.23 (t, J = 7.3,
3H, CH3), 4.10 (q, J = 7.3, 2H, CH2), 5.79 (s, 2H, CH2), 6.20 (s, 1H,
OH), 6.62 (d, J = 8.8, 1H, ArH), 7.11–7.23 (m, 3H, 2ArH and CH),
7.94 (d, J = 8.5, 1H, ArH), 8.11 (s, 1H, ArH), 8.20 (d, J = 7.2, 1H,
ArH), 8.49 (s, 1H, ArH). Anal. Calcd for C23H16ClF6NO4: C: 53.14;
H: 3.10; N: 2.69. Found: C: 53.29; H: 3.27; N: 2.83.
4.4.5. Ethyl 4-[1-(3,5-dimethylbenzyl)-5-chloro-1H-indol-3-yl]-
2-hydroxy-4-oxobut-2-enoate (10e)
Mp 215–217 C, yield 89%; 1H NMR (DMSO-d6): 1.25 (t, J = 7.2,
3H, CH3), 2.20 (s, 6H, CH3), 4.09 (q, J = 7.2, 2H, CH2), 5.37 (s, 2H,
CH2), 6.17 (s, 1H, ArH), 6.86–6.89 (m, 3H, 2ArH and CH), 7.13 (d,Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2J = 8.8, 1H, ArH), 7.46 (d, J = 8.8, 1H, ArH), 8.13 (d, J = 6.1, 1H,
ArH), 8.44 (s, 1H, ArH). Anal. Calcd for C23H22ClNO4: C: 67.07; H:
5.38; N: 3.40. Found: C: 67.30; H: 5.41; N: 3.67.
4.4.6. Ethyl 4-[1-(2,4,6-trimethylbenzyl)-5-chloro-1H-indol-3-
yl]-2-hydroxy-4-oxobut-2-enoate (10f)
Mp 150–152 C, yield 97%; 1H NMR (DMSO-d6): 1.27 (t, J = 7.2,
3H, CH3), 2.16 (s, 6H, CH3), 2.26 (s, 3H, CH3), 4.26 (q, J = 7.2, 2H,
CH2), 5.44 (s, 2H, CH2), 6.81 (s, 1H, ArH), 6.95 (s, 2H, ArH and
CH), 7.35 (d, J = 8.5, 1H, ArH), 7.63 (d, J = 8.8, 1H, ArH), 8.17 (s,
1H, ArH), 8.24 (s, 1H, ArH). Anal. Calcd for C24H24ClNO4: C:
67.68; H: 5.68; N: 3.29. Found: C: 67.85; H: 5.79; N: 3.16.
4.4.7. Ethyl 4-[1-(4-phenylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoate (11a)
Mp 168 C dec, yield 92%; 1H NMR (DMSO-d6) 1.14 (t, J = 7.3, 3H,
CH3), 3.94 (q, J = 7.3, 2H, CH2), 5.50 (s, 2H, CH2), 6.25 (br s, 1H, OH),
6.96–8.28 (m, 14H, ArH and CH). Anal. Calcd for C27H22FNO4: C,
73.13; H, 5.00; N, 3.16. Found: C, 73.38; H, 4.16; N 3.01.
4.4.8. Ethyl 4-{1-[4-(triﬂuoromethyl)benzyl]-5-ﬂuoro-1H-indol-
3-yl}-2-hydroxy-4-oxobut-2-enoate (11b)
Mp 217 C dec, yield 60%; 1H NMR (DMSO-d6): 1.23 (t, J = 7.3,
3H, CH3), 4.09 (q, J = 7.3, 2H, CH2), 5.57 (s, 2H, CH2), 6.17 (s, 1H,
OH), 6.96 (t, J = 9, 1H, ArH), 7.35–7.42 (m, 4H, 3ArH and CH),
7.68 (d, J = 8.1, 2H, ArH), 8.12 (s, 1H, ArH), 8.23 (s, 1H, ArH). Anal.
Calcd for C22H17F4NO4: C: 60.69; H: 3.94; N: 3.22. Found: C:
60.46; H: 4.11; N: 3.37.
4.4.9. Ethyl 4-[1-(4-tert-butylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoate (11c)
Mp 227 C dec, yield 88%; 1H NMR (DMSO-d6): 1.20 (s, 9H, CH3),
1.24 (t, J = 6.9, 3H, CH3), 4.07 (d, J = 6.9, 2H, CH2), 5.38 (s, 2H, CH2),
6.14 (s, 1H, ArH), 6.92–6.99 (m, 1H, ArH), 7.13–7.19 (m, 2H, ArH
and CH), 7.29–7.38 (m, 2H, ArH), 7.47 (d, J = 9, 1H, ArH), 8.09 (d,
J = 8.5, 1H, ArH), 8.51 (s, 1H, ArH). Anal. Calcd for C25H26FNO4: C:
70.91; H: 6.19; N: 3.31. Found: C: 71.04; H: 6.28; N: 3.51.
4.4.10. Ethyl 4-{1-[2,4-bis(triﬂuoromethyl)benzyl]-5-ﬂuoro-1H-
indol-3-yl}-2-hydroxy-4-oxobut-2-enoate (11d)
Mp 269–271 C, yield 99%; 1H NMR (DMSO-d6) 1.23 (t, J = 7.3,
3H, CH3), 4.10 (q, J = 7.3, 2H, CH2), 5.72 (s, 2H, CH2), 6.21 (s, 1H,
OH), 6.58–8.41 (m, 8H, ArH and CH). Anal. Calcd for C23H16F7NO4:
C, 54.88; H, 3.20; N, 2.78. Found: C, 54.96; H, 3.27; N, 3.35.
4.4.11. Ethyl 4-[1-(3,5-dimethylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-
2-hydroxy-4-oxobut-2-enoate (11e)
Mp 170–172 C, yield 93%; 1H NMR (DMSO-d6): 1.23 (t, J = 7.4,
3H, CH3), 2.19 (s, 6H, CH3), 4.09 (q, J = 7.4, 2H, CH2), 5.34 (s, 2H,
CH2), 6.16 (s, 1H, ArH), 6.86–6.98 (m, 4H, 3ArH and CH), 7.41 (d,
J = 8.5, 1H, ArH), 7.93 (s, 1H, ArH), 8.11 (d, J = 6.4, 1H, ArH), 8.50
(s, 1H, ArH). Anal. Calcd for C23H22FNO4: C: 69.51; H: 6.09; N:
3.52. Found: C: 69.76; H: 6.24; N: 3.77.
4.4.12. Ethyl 4-[1-(2,4,6-trimethylbenzyl)-5-ﬂuoro-1H-indol-3-
yl]-2-hydroxy-4-oxobut-2-enoate (11f)
Mp 177–179 C, yield 94%; 1H NMR (DMSO-d6): 1.20 (t, J = 7.3,
3H, CH3), 2.16 (s, 6H, CH3), 2.27 (s, 3H, CH3), 4.05 (q, J = 7.3, 2H,
CH2), 5.28 (s, 2H, CH2), 5.94 (d, J = 4.7, 1H, ArH), 6.19 (s, 1H, ArH),
6.96–7.03 (m, 2H, ArH and CH), 7.20 (s, 1H, ArH), 7.56 (t, J = 8.5,
1H, ArH), 8.06 (m, 1H, ArH). Anal. Calcd for C24H24FNO4: C:
70.40; H: 5.91; N: 3.42. Found: C: 70.23; H: 6.07; N: 3.24
4.4.13. Ethyl 4-[1-(4-phenylbenzyl)-5-methoxy-1H-indol-3-yl]-
2-hydroxy-4-oxobut-2-enoate (12a)
Mp 164 C dec, yield 95%; 1H NMR (DMSO-d6) 1.24 (t, J = 7.3, 3H,
CH3), 3.75 (s, 3H, OCH3) 3.93 (q, J = 7.3, 2H, CH2), 5.46 (s, 2H, CH2),014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
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C28H25FNO5: C, 73.83; H, 5.53; N, 3.08. Found: C, 73.55; H, 5.27; N
3.01.
4.4.14. Ethyl 4-{1-[4-(triﬂuoromethyl)benzyl]-5-methoxy-1H-
indol-3-yl}-2-hydroxy-4-oxobut-2-enoate (12b)
Mp 223 C dec, yield 92%; 1H NMR (DMSO-d6): 1.23 (t, J = 7.3,
3H, CH3), 3.74 (s, 3H, OCH3), 4.09 (q, J = 7.3, 2H, CH2), 5.52 (s, 2H,
CH2), 6.19 (s, 1H, OH), 6.74 (d, J = 8.8, 1H, ArH), 7.27 (d, J = 9.1,
1H, ArH), 7.30–7.39 (m, 3H, 2ArH and CH), 7.68 (d, J = 7.9, 2H,
ArH), 7.92 (s, 1H, ArH), 8.09 (s, 1H, ArH). Anal. Calcd for C23H20F3-
NO5: C: 61.75; H: 4.51; N: 3.13. Found: C: 61.92; H: 4.38; N: 3.29.
4.4.15. Ethyl 4-[1-(4-tert-butylbenzyl)-5-methoxy-1H-indol-3-
yl]-2-hydroxy-4-oxobut-2-enoate (12c)
Mp 150–152 C, yield 91%; 1H NMR (DMSO-d6): 1.16 (s, 9H,
CH3), 1.20 (t, J = 6.9, 3H, CH3), 3.69 (s, 3H, OCH3), 3.89 (d, J = 6.9,
2H, CH2), 5.30 (s, 2H, CH2), 6.22 (s, 1H, OH), 6.65 (d, J = 8.5, 1H,
ArH), 7.13 (d, J = 8.5, 2H, ArH), 7.28 (m, 4H, 3ArH and CH), 7.82
(s, 1H, ArH), 8.42 (s, 1H, ArH). Anal. Calcd for C25H27NO5: C:
71.70; H: 6.71; N: 3.22. Found: C: 71.97; H: 6.91; N: 3.45.
4.4.16. Ethyl 4-{1-[2,4-bis(triﬂuoromethyl)benzyl]-5-methoxy-
1H-indol-3-yl}-2-hydroxy-4-oxobut-2-enoate (12d)
Mp 166–168 C, yield 68%; 1H NMR (DMSO-d6): 1.29 (t, J = 7.3,
3H, CH3), 3.80 (s, 3H, OCH3), 3.95 (q, J = 7.3, 2H, CH2), 5.81 (s, 2H,
CH2), 6.76 (d, J = 8.1, 1H, ArH), 6.88–6.92 (m, 2H, ArH and CH),
7.24 (d, J = 8.9, 1H, ArH), 7.80 (s, 1H, ArH), 7.95 (d, J = 8.1, 1H,
ArH), 8.13 (s, 1H, ArH), 8.81 (s, 1H, ArH). Anal. Calcd for C24H19F6-
NO5: C: 55.93; H: 3.72; N: 2.72. Found: C: 56.11; H: 3.98; N: 2.89.
4.4.17. Ethyl 4-[1-(3,5-dimethylbenzyl)-5-methoxy-1H-indol-3-
yl]-2-hydroxy-4-oxobut-2-enoate (12e)
Mp 240–242 C, yield 89%; 1H NMR (DMSO-d6): 1.26 (t, J = 7.2,
3H, CH3), 2.20 (s, 6H, CH3), 3.76 (s, 3H, OCH3), 3.95 (q, J = 7.2, 2H,
CH2), 5.33 (s, 2H, CH2), 6.29 (s, 1H, ArH), 6.78 (d, J = 8.2, 1H, ArH),
6.86–6.98 (m, 2H, ArH and CH), 7.32 (d, J = 8.8, 1H, ArH), 7.89 (s,
1H, ArH), 8.10 (s, 1H, ArH), 8.48 (s, 1H, ArH). Anal. Calcd for
C24H25NO5: C: 70.75; H: 6.18; N: 3.44. Found: C: 70.67; H: 6.40;
N: 3.58.
4.4.18. Ethyl 4-[1-(2,4,6-trimethylbenzyl)-5-methoxy-1H-indol-
3-yl]-2-hydroxy-4-oxobut-2-enoate (12f)
Mp 157–159 C, yield 98%; 1H NMR (DMSO-d6): 1.27 (t, J = 7.1,
3H, CH3), 2.17 (s, 6H, CH3), 2.25 (s, 3H, CH3), 3.79 (s, 3H, OCH3),
4.26 (q, J = 7.1, 2H, CH2), 5.40 (s, 2H, CH2), 6.79 (s, 1H, ArH),
6.92–6.94 (m, 3H, 2ArH and CH), 7.48 (d, J = 8.8, 1H, ArH), 7.75
(s, 1H, ArH), 8.04 (s, 1H, ArH). Anal. Calcd for C25H27NO5: C:
71.24; H: 6.46; N: 3.32. Found: C: 71.51; H: 6.28; N: 3.46.
4.5. General procedure for the synthesis of 4-[1-benzyl-1H-
indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acids (13–15 a–f)
Following the synthetic procedure previously reported by
us,18,19,29,31 the appropriate 4-[1-benzyl-1H-indol-3-yl]-2-hydro-
xy-4-oxobut-2-enoate (10–12 a–f) (1 mmol) was dissolved in
methanol (5 ml) and treated with 2 N NaOH (5 ml, 50 mmol). The
reaction mixture was stirred at room temperature for 1.5 h and
then acidiﬁed with conc. HCl to give the corresponding hydrolysed
derivative. The desired products were crystallized from a mixture
of ethanol and diethyl ether (1:4).
4.5.1. 4-[1-(4-Phenylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (13a)
Mp 220 C dec, yield 78%; 1H NMR (DMSO-d6): 5.59 (s, 2H, CH2),
7.03 (s, 1H, ArH), 7.33 (t, J = 9, 2H, ArH), 7.39–7.45 (m, 3H, 2ArHPlease cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2and CH), 7.59–7.63 (m, 4H, ArH), 7.73 (d, J = 9, 2H, ArH), 8.21 (s,
1H, ArH), 9.18 (s, 1H, ArH). Anal. Calcd for C25H18ClNO4: C:
69.53; H: 4.20; N: 3.24. Found: C: 69.64; H: 4.42; N: 3.38.
4.5.2. 4-{1-[4-(Triﬂuoromethyl)benzyl]-5-chloro-1H-indol-3-
yl}-2-hydroxy-4-oxobut-2-enoic acid (13b)
Mp 176–178 C, yield 30%; 1H NMR (DMSO-d6): 5.63 (s, 2H,
CH2), 6.98 (s, 1H, CH), 7.30 (d, J = 9, 1H, ArH), 7.49 (d, J = 8, 2H,
ArH), 7.62–7.72 (m, 3H, ArH), 8.21 (s, 1H, ArH), 9.07 (s, 1H, ArH).
Anal. Calcd for C20H13ClF3NO4: C: 56.69; H: 3.09; N: 3.31. Found:
C: 56.87; H: 3.32; N: 3.49.
4.5.3. 4-[1-(4-tert-Butylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (13c)
Mp 109–111 C, yield 51%; 1H NMR (DMSO-d6): 1.20 (s, 9H,
CH3), 5.46 (s, 2H, CH2), 6.98 (s, 1H, CH), 7.25–7.35 (m, 5H, ArH),
7.69 (d, J = 9.1, 1H, ArH), 8.20 (s, 1H, ArH), 9.06 (s, 1H, ArH). Anal.
Calcd for C23H22ClNO4: C: 67.07; H: 5.38, N: 3.40. Found: C:
67.24; H: 5.21, N: 3.29.
4.5.4. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-chloro-1H-indol-
3-yl}-2-hydroxy-4-oxobut-2-enoic acid (13d)
Mp 365–367 C, yield 38%; 1H NMR (DMSO-d6): 5.85 (s, 2H,
CH2), 6.79 (t, J = 8.5, 1H, ArH), 6.94 (s, 1H, CH), 7.32 (d, J = 9.6,
1H, ArH), 7.45 (d, J = 8.5, 1H, ArH), 7.95 (d, J = 7.5, 1H, ArH), 8.14
(s, 1H, ArH), 8.28 (s, 1H, ArH), 8.97 (s, 1H, ArH). Anal. Calcd for C21-
H12ClF6NO4: C: 51.29; H: 2.46; N: 2.85. Found: C: 51.42; H: 2.77; N,
3.03.
4.5.5. 4-[1-(3,5-Dimethylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (13e)
Mp 157–159 C, yield 71%; 1H NMR (DMSO-d6): 2.21 (s, 6H,
CH3), 5.44 (s, 2H, CH2), 6.94 (d, J = 7.5, 3H, ArH), 6.98 (s, 1H, CH),
7.31 (d, J = 8.9, 1H, ArH), 7.65 (d, J = 8.9, 1H, ArH), 8.21 (s, 1H,
ArH), 9.05 (s, 1H, ArH). Anal. Calcd for C21H18ClNO4: C: 65.71; H:
4.73; N: 3.65. Found: C: 65.85; H: 4.68; N: 3.94.
4.5.6. 4-[1-(2,4,6-Trimethylbenzyl)-5-chloro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (13f)
Mp 238–240 C, yield 59%; 1H NMR (DMSO-d6): 2.18 (s, 6H,
CH3), 2.24 (s, 3H, CH3), 5.42 (s, 2H, CH2), 6.82 (s, 1H, CH), 6.97 (s,
2H, ArH), 7.20–7.23 (m, 1H, ArH), 7.61–7.64 (m, 1H, ArH), 7.92–
7.95 (m, 1H, ArH), 8.15 (s, 1H, ArH). Anal. Calcd for C22H20ClNO4:
C: 66.42; H: 5.07; N: 3.52. Found: C: 66.55; H: 5.19; N: 3.41.
4.5.7. 4-[1-(4-Phenylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (14a)
Mp 173–175 C, yield 42%; 1H NMR (DMSO-d6): 5.56 (s, 2H,
CH2), 6.98 (s, 1H, ArH), 7.15 (t, J = 8.1, 1H, ArH), 7.32 (d, J = 6.8,
1H, ArH), 7.35–7.45 (m, 4H, 3ArH and CH), 7.59–7.70 (m, 5H,
ArH), 9.08 (s, 1H, ArH). Anal. Calcd for C25H18FNO4: C: 72.28; H:
4.37; N: 3.37. Found: C: 72.44; H: 4.15; N: 3.21.
4.5.8. 4-{1-[4-(Triﬂuoromethyl)benzyl]-5-ﬂuoro-1H-indol-3-
yl}-2-hydroxy-4-oxobut-2-enoic acid (14b)
Mp 174 C dec, yield 48%; 1H NMR (DMSO-d6): 5.64 (s, 2H, CH2),
6.98 (s, 1H, CH), 7.16 (t, J = 9.4, 1H, ArH), 7.52 (d, J = 8.2, 2H, ArH),
7.63 (d, J = 8.9, 1H, ArH), 7.71 (d, J = 8.2, 1H, ArH), 7.91 (d, J = 9.4,
1H, ArH), 9.08 (s, 1H, ArH). Anal. Calcd for C20H13F4NO4: C:
58.98; H: 3.22; N: 3.44. Found: C: 59.14; H: 3.47; N: 3.24.
4.5.9. 4-[1-(4-tert-Butylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (14c)
Mp 186–188 C, yield 55%; 1H NMR (DMSO-d6): 1.22 (s, 9H,
CH3), 5.49 (s, 2H, CH2), 6.98 (s, 1H, CH), 7.11–7.20 (m, 1H, ArH),
7.29–7.37 (m, 4H, ArH), 7.68–7.72 (m, 1H, ArH), 7.99 (d, J = 9.4,014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxx 91H, ArH), 9.08 (s, 1H, ArH). Anal. Calcd for C23H22FNO4: C: 69.86; H:
5.61; N: 3.54. Found: C: 69.99; H: 5.52; N: 3.59.
4.5.10. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-ﬂuoro-1H-indol-
3-yl}-2-hydroxy-4-oxobut-2-enoic acid (14d)
Mp 237–239 C, yield 61%; 1H NMR (DMSO-d6): 5.82 (s, 2H,
CH2), 6.79 (d, J = 8.1, 1H, ArH), 6.95 (s, 1H, CH), 7.16 (t, J = 9.4,
1H, ArH), 7.39 (d, J = 8.9, 1H, ArH), 7.97 (d, J = 9.4, 1H, ArH), 8.25
(s, 1H, ArH), 8.97 (s, 1H, ArH). Anal. Calcd for C21H12F7NO4: C:
53.07; H: 2.54; N: 2.95. Found: C: 53.25; H: 2.32; N: 3.09.
4.5.11. 4-[1-(3,5-Dimethylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (14e)
Mp 231–233 C, yield 98%; 1H NMR (DMSO-d6): 2.21 (s, 6H,
CH3), 5.43 (s, 2H, CH2), 6.92–6.99 (m, 4H, 3ArH and CH), 7.13–
7.20 (m, 1H, ArH), 7.61–7.65 (m, 1H, ArH), 7.88–7.92 (m, 1H,
ArH), 9.05 (s, 1H, ArH). Anal. Calcd for C21H18FNO4: C: 68.66; H:
4.94; N: 3.81. Found: C: 68.50; H: 5.18; N: 3.94.
4.5.12. 4-[1-(2,4,6-Trimethylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (14f)
Mp 110–112 C, yield 14%; 1H NMR (DMSO-d6): 2.17 (s, 6H,
CH3), 2.26 (s, 3H, CH3), 5.44 (s, 2H, CH2), 6.80 (s, 1H, CH), 6.95 (s,
2H, ArH), 7.19–7.23 (m, 1H, ArH), 7.62–7.66 (m, 1H, ArH), 7.91–
7.95 (m, 1H, ArH), 8.13 (s, 1H, ArH). Anal. Calcd for C22H20FNO4:
C: 69.28; H: 5.29; N: 3.67. Found: C: 69.46; H: 5.15; N: 3.48.
4.5.13. 4-[1-(4-Phenylbenzyl)-5-methoxy-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (15a)
Mp 170–172 C, yield 64%; 1H NMR (DMSO-d6): 3.78 (s, 3H,
OCH3), 5.52 (s, 2H, CH2), 6.90 (d, J = 8.5, 1H, ArH), 6.97 (s, 1H,
ArH), 7.34 (d, J = 7.3, 1H, ArH), 7.40–7.45 (m, 4H, 3ArH and CH),
7.55 (d, J = 8.9, 1H, ArH), 7.59–7.63 (m, 4H, ArH), 7.74 (s, 1H,
ArH), 8.97 (s, 1H, ArH). Anal. Calcd for C26H21NO5: C: 73.06; H:
4.95; N: 3.28. Found: C: 73.26; H: 4.81; N: 3.08.
4.5.14. 4-{1-[4-(Triﬂuoromethyl)benzyl]-5-methoxy-1H-indol-
3-yl}-2-hydroxy-4-oxobut-2-enoic acid (15b)
Mp 178–180 C, yield 72%; 1H NMR (DMSO-d6) 3.80 (s, 3H,
OCH3), 5.61 (s, 2H, CH2), 6.97–7.78 (m, 8H, ArH and CH), 8.98 (s,
1H, ArH). Anal. Calcd for C21H16F3NO5: C, 60.15; H, 3.38; N, 3.34.
Found: C, 60.23; H, 3.57; N, 3.56.
4.5.15. 4-[1-(4-tert-Butylbenzyl)-5-methoxy-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (15c)
Mp 177–179 C, yield 26%; 1H NMR (DMSO-d6): 1.19 (s, 9H,
CH3), 3.74 (s, 3H, OCH3), 5.42 (s, 2H, CH2), 6.88 (d, J = 9, 1H, ArH),
6.95 (s, 1H, CH), 7.29 (d, J = 8.5, 4H, ArH), 7.52 (d, J = 9, 1H, ArH),
7.70 (s, 1H, ArH), 8.94 (s, 1H, ArH). Anal. Calcd for C24H25NO5: C:
70.74; H: 6.18; N: 3.44. Found: C: 70.92; H: 6.34; N: 3.70.
4.5.16. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-methoxy-1H-
indol-3-yl}-2-hydroxy-4-oxobut-2-enoic acid (15d)
Mp 198–200 C, yield 72%; 1H NMR (DMSO-d6): 3.80 (s, 3H,
OCH3), 5.80 (s, 2H, CH2), 6.79 (d, J = 8.1, 1H, ArH), 6.89 (s, 1H,
ArH), 6.92 (s, 1H, CH), 7.26 (d, J = 8.9, 1H, ArH), 7.80 (s, 1H, ArH),
7.96 (d, J = 8.1, 1H, ArH), 8.13 (s, 1H, ArH), 8.86 (s, 1H, ArH). Anal.
Calcd for C22H15F6NO5: C: 54.22; H: 3.10; N: 2.87. Found: C:
54.35; H: 3.32; N: 3.04.
4.5.17. 4-[1-(3,5-Dimethylbenzyl)-5-methoxy-1H-indol-3-yl]-2-
hydroxy-4-oxobut-2-enoic acid (15e)
Mp 180–182 C, yield 45%; 1H NMR (DMSO-d6): 2.20 (s, 6H,
CH3), 3.78 (s, 3H, OCH3), 5.38 (s, 2H, CH2), 6.87–6.96 (m, 5H,
4ArH and CH), 7.47 (d, J = 9.1, 1H ArH), 7.74 (s, 1H, ArH), 8.87 (s,Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (21H, ArH). Anal. Calcd for C22H21NO5: C: 69.65; H: 5.58; N: 3.69.
Found: C: 69.46; H: 5.81; N: 3.77.
4.5.18. 4-[1-(2,4,6-Trimethylbenzyl)-5-methoxy-1H-indol-3-yl]-
2-hydroxy-4-oxobut-2-enoic acid (15f)
Mp 204–206 C, yield 49%; 1H NMR (DMSO-d6): 2.18 (s, 6H,
CH3), 2.27 (s, 3H, CH3), 3.80 (s, 3H, OCH3), 5.40 (s, 2H, CH2), 6.76
(s, 1H, CH), 6.92–6.95 (m, 3H, ArH), 7.51 (d, J = 9, 1H, ArH), 7.76
(s, 1H, ArH), 8.00 (s, 1H, ArH). Anal. Calcd for C23H23NO5: C:
70.22; H: 5.89; N: 3.56. Found: C: 69.98; H: 5.97; N: 3.85.
4.6. General procedure for the synthesis of 4-[1-benzyl-1H-
indol-3-oyl)]-3-hydroxyfuran-2(5H)-ones (16–18 a–f)
Adopting the synthetic procedure previously reported by us32, a
solution of 40% aqueous formaldehyde in water (4 ml) was added
to a mixture of 13–15 a–f (1 mmol) in diethyl ether (5 ml). The stir-
ring was then continued until clear layers were formed (usually
within 1–2 h). The clear, aqueous bottom layer was removed and
the organic layer extracted twice with 5 ml of water. The combined
aqueous extracts were cooled followed by acidiﬁcation with 3 ml
of concentrated hydrochloric acid. The corresponding furanone
precipitate was collected, dried and recrystallized from ethanol.
4.6.1. 4-[1-(4-Phenylbenzyl)-5-chloro-1H-indol-3-yl)-3-
hydroxyfuran-2(5H)-one (16a)
Mp 199–201 C, yield 69%; 1H NMR (DMSO-d6): 5.12 (s, 2H,
CH2), 5.60 (s, 2H, CH2), 7.29–8.81 (m, 13H, ArH). Anal. Calcd for C26-
H18ClNO4: C: 70.35; H: 4.09; N: 3.16. Found: C: 70.54; H: 4.29; N:
3.42.
4.6.2. 4-[1-(4-Triﬂuoromethylbenzyl)-5-chloro-1H-indol-3-yl)-
3-hydroxyfuran-2(5H)-one (16b)
Mp 212–214 C, yield 32%; 1H NMR (DMSO-d6): 5.12 (s, 2H,
CH2), 5.59 (s, 2H, CH2), 7.10–7.85 (m, 7H, ArH), 8.79 (s, 1H, ArH).
Anal. Calcd for C21H13ClF3NO4: C: 57.88; H: 3.01; N: 3.21. Found:
C: 57.63; H: 3.22; N: 3.41.
4.6.3. 4-[1-(4-tert-Butylbenzyl)-5-chloro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (16c)
Mp 179–181 C, yield 26%;1H NMR (DMSO-d6): 1.23 (s, 9H,
CH3), 5.13 (s, 2H, CH2), 5.51 (s, 2H, CH2), 7.26 (t, J = 8.3, 3H, ArH),
7.33 (t, J = 8.3, 3H, ArH), 7.65 (d, J = 8.8, 1H, ArH), 8.22 (s, 1H,
ArH), 8.77 (s, 1H, OH). Anal. Calcd for C24H22ClNO4:C: 68.00; H:
5.23; N: 3.30. Found: C: 68.11; H: 5.34; N: 3.21.
4.6.4. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-chloro-1H-indol-
3-yl}-3-hydroxyfuran-2(5H)-one (16d)
Mp 231–233 C, yield 44%; 1H NMR (DMSO-d6): 5.10 (s, 2H,
CH2), 5.87 (s, 2H, CH2), 6.88–8.69 (m, 7H, ArH). Anal. Calcd for C22-
H12ClF6NO4: C, 52.45; H, 2.40; N, 2.78. Found: C, 52.39; H, 2.52; N,
2.89.
4.6.5. 4-[1-(3,5-Dimethylbenzyl)-5-chloro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (16e)
Mp 215–217 C, yield 63%; 1H NMR (DMSO-d6): 2.19 (s, 6H,
CH3), 5.10 (s, 2H, CH2), 5.44 (s, 2H, CH2), 6.91 (s, 3H, ArH), 7.28
(d, J = 8.5, 1H, ArH), 7.58 (d, J = 8.5, 1H, ArH), 8.20 (s, 1H, ArH),
8.70 (s, 1H, ArH). Anal. Calcd for C22H18ClNO4: C: 66.75; H: 4.58;
N: 3.54. Found: C: 66.63; H: 4.75; N: 3.70.
4.6.6. 4-[1-(2,4,6-Trimethylbenzyl)-5-chloro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (16f)
Mp 228–230 C, yield 48%; 1H NMR (DMSO-d6): 2.19 (s, 6H,
CH3), 2.25 (s, 3H, CH3), 4.94 (s, 2H, CH2), 5.38 (s, 2H, CH2), 6.94
(s, 2H, ArH), 7.37 (d, J = 8.5, 1H, ArH), 7.79 (d, J = 8.5, 1H, ArH),014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
10 S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxx8.24 (s, 2H, ArH). Anal. Calcd for C23H20ClNO4: C: 67.40; H: 4.92; N:
3.42. Found: C: 67.55; H: 5.02; N: 3.67.
4.6.7. 4-[1-(4-Phenylbenzyl)-5-ﬂuoro-1H-indol-3-yl)-3-
hydroxyfuran-2(5H)-one (17a)
Mp 165–167 C, yield 41%; 1H NMR (CDCl3): 5.12 (s, 2H, CH2),
5.60 (s, 2H, CH2), 7.11-8.81 (m, 13H, ArH). Anal. Calcd for C26H18-
FNO4: C, 73.06; H, 4.24; N, 3.28. Found: C, 73.23; H, 4.43; N, 3.12.
4.6.8. 4-[1-(4-Triﬂuoromethylbenzyl)-5-ﬂuoro-1H-indol-3-yl)-
3-hydroxyfuran-2(5H)-one (17b)
Mp 209–211 C, yield 42%; 1H NMR (DMSO-d6): 5.10 (s, 2H,
CH2), 5.67 (s, 2H, CH2), 7.08–7.95 (m, 7H, ArH), 8.86 (s, 1H, ArH).
Anal. Calcd for C21H13F4NO4: C, 61.15; H, 3.12; N, 3.34. Found: C,
61.35; H, 3.08; N, 3.27.
4.6.9. 4-[1-(4-tert-Butylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (17c)
Mp 229–231 C, yield 29%; 1H NMR (DMSO-d6): 1.23 (s, 9H,
CH3), 4.87 (s, 2H, CH2), 5.42 (s, 2H, CH2),7.00 (t, J = 8.8, 1H, ArH),
7.17 (d, J = 8.3, 2H, ArH), 7.34 (d, J = 7.1, 2H, ArH), 7.51–7.55 (m,
1H, ArH), 8.12 (d, J = 9.4, 1H, ArH), 10.30 (s, 1H, ArH). Anal. Calcd
for C24H22FNO4:C: 70.75; H: 5.44; N: 3.44. Found: C: 70.89; H:
5.23; N: 3.55.
4.6.10. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-ﬂuoro-1H-indol-
3-yl}-3-hydroxyfuran-2(5H)-one (17d)
Mp 232–234 C, yield 59%; 1H NMR (DMSO-d6): 5.19 (s, 2H,
CH2), 5.73 (s, 2H, CH2), 6.72–8.54 (m, 7H, ArH). Anal. Calcd for C22-
H12F7NO4: C, 54.22; H, 2.48; N, 2.87. Found: C, 54.46; H, 2.61; N,
2.74.
4.6.11. 4-[1-(3,5-Dimethylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (17e)
Mp 230–232 C, yield 78%; 1H NMR (DMSO-d6): 2.21 (s, 6H,
CH3), 5.13 (s, 2H, CH2), 5.46 (s, 2H, CH2), 6.91–6.95 (m, 3H, ArH),
7.12–7.18 (m, 1H, ArH), 7.58–7.62 (m, 1H, ArH), 7.89–7.93 (m,
1H, ArH), 8.68 (s, 1H, ArH). Anal. Calcd for C22H18FNO4: C: 69.65;
H: 4.78; N: 3.69. Found: C: 69.81; H: 4.92; N: 3.89.
4.6.12. 4-[1-(2,4,6-Trimethylbenzyl)-5-ﬂuoro-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (17f)
Mp 202–204 C, yield 44%; 1H NMR (DMSO-d6): 2.20 (s, 6H,
CH3), 2.27 (s, 3H, CH3), 4.98 (s, 2H, CH2), 5.40 (s, 2H, CH2), 6.97
(s, 2H, ArH), 7.39 (d, J = 8.5, 1H, ArH), 7.76 (d, J = 8.5, 1H, ArH),
8.22 (s, 2H, ArH). Anal. Calcd for C23H20FNO4: C: 70.22; H: 5.12;
N: 3.56. Found: C: 70.50; H: 5.23; N: 3.69.
4.6.13. 4-[1-(4-Phenylbenzyl)-5-methoxy-1H-indol-3-yl)-3-
hydroxyfuran-2(5H)-one (18a)
Mp 209–211 C, yield 49%; 1H NMR (DMSO-d6): 3.77 (s, 3H,
CH3), 5.15 (s, 2H, CH2), 5.55 (s, 2H, CH2), 6.86-8.60 (m, 13H, ArH).
Anal. Calcd for C27H21NO5:C, 73.79; H, 4.82; N, 3.19. Found: C,
73.52; H, 4.61; N, 3.34.
4.6.14. 4-[1-(4-Triﬂuoromethylbenzyl)-5-methoxy-1H-indol-3-
yl)-3-hydroxyfuran-2(5H)-one (18b)
Mp 213–215 C, yield 38%; 1H NMR (DMSO-d6): 3.76 (s, 3H,
CH3), 5.10 (s, 2H, CH2), 5.62 (s, 2H, CH2), 6.85–7.80 (m, 7H, ArH),
8.79 (s, 1H, ArH). Anal. Calcd for C22H16F3NO5: C, 61.26; H, 3.74;
N, 3.25. Found: C, 61.44; H, 3.58; N, 3.39.
4.6.15. 4-[1-(4-tert-Butylbenzyl)-5-methoxy-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (18c)
Mp 219–221 C, yield 38%;1H NMR (DMSO-d6): 1.21 (s, 9H,
CH3), 3.76 (s, 3H, OCH3), 5.13 (s, 2H, CH2), 5.44 (s, 2H, CH2), 6.87Please cite this article in press as: Ferro, S.; et al. Bioorg. Med. Chem. (2(d, J = 9.0, 1H, ArH), 7.28 (dd, J = 8.5, 4H, ArH), 7.49 (d, J = 9.0, 1H,
ArH), 7.76 (s, 1H, ArH), 8.59 (s, 1H, ArH). Anal. Calcd for
C24H27NO5: C: 71.24; H: 6.46; N: 3.32. Found: C: 71.09; H: 6.37;
N: 3.22.
4.6.16. 4-{1-[2,4-Bis(triﬂuoromethyl)benzyl]-5-methoxy-1H-
indol-3-yl}-3-hydroxyfuran-2(5H)-one (18d)
Mp 223–225 C, yield 68%; 1H NMR (DMSO-d6): 3.79 (s, 3H,
OCH3), 5.12 (s, 2H, CH2), 5.83 (s, 2H, CH2), 6.83–8.13 (m, 6H,
ArH), 8.60 (s, 1H, ArH). Anal. Calcd for C23H15F6NO5: C, 55.32; H,
3.03; N, 2.80. Found: C, 55.29; H, 3.37; N, 2.89.
4.6.17. 4-[1-(3,5-Dimethylbenzyl)-5-methoxy-1H-indol-3-yl]-3-
hydroxyfuran-2(5H)-one (18e)
Mp 198–200 C, yield 65%; 1H NMR (DMSO-d6): 2.21 (s, 6H,
CH3), 3.76 (s, 3H, OCH3), 5.15 (s, 2H, CH2), 5.41 (s, 2H, CH2),
6.88–6.93 (m, 4H, ArH), 7.45 (d, J = 8.8, 1H, ArH) 7.77 (s, 1H,
ArH), 8.54 (s, 1H, ArH). Anal. Calcd for C22H18NO5: C: 70.20; H:
4.82; N: 3.72. Found: C: 70.35; H: 4.99; N: 3.93.
4.6.18. 4-[1-(2,4,6-Trimethylbenzyl)-5-methoxy-1H-indol-3-yl]-
3-hydroxyfuran-2(5H)-one (18f)
Mp 191–193 C, yield 52%; 1H NMR (DMSO-d6): 2.19 (s, 6H,
CH3), 2.25 (s, 3H, CH3), 3.79 (s, 3H, OCH3),4.96 (s, 2H, CH2), 5.34
(s, 2H, CH2), 6.91–7.01 (m, 3H, ArH), 7.63 (d, J = 8.8, 1H, ArH),
7.79 (s, 1H, ArH), 7.94 (s, 1H, ArH). Anal. Calcd for C24H23NO5: C:
71.10; H: 5.72; N: 3.45. Found: C: 71.29; H: 5.91; N: 3.63.
4.7. Docking studies
Docking calculations were carried out using the same protocol
that we successfully applied in our previous papers,20,34,37,38 using
Gold software39 and GoldScore scoring function.
Regarding docking into the LEDGF/p75 binding pocket, the crys-
tal structure of the dimeric INCCD complexed with the LEDGF/
p75IBD was retrieved from the RCSB Protein Data Bank (entry code
2B4J).40 The LEDGF structure was removed and hydrogen atoms
were added to the IN protein in Discovery Studio 2.5.5.41 The stan-
dard default settings were used in all calculations. A 20.0 Å radius
active site was drawn on the original position of the LEDGFIBD
dipeptide Ile365-Asp366 and automated cavity detection was
used. Results differing by less than 0.75 Å in ligand-all atom RMSD
were clustered together. Two rotatable bonds of the diketo acid
moiety of the ligands were kept ﬁxed during docking calculation.
The two molecules containing the diketo acid moiety were simu-
lated in the mono-ionized form.
Docking studies on IN catalytic site were performed using the
crystal structure of PFV–IN with DNA and two Mg ions complexed
with the inhibitor raltegravir, retrieved from the RCSB Protein Data
Bank (PDB code 3OYA).42 Hydrogen atoms were added using Dis-
covery Studio 2.5.5 and the structure of raltegravir was removed.
A 15 Å radius active site was deﬁned considering the coordinates
of raltegravir in the X-ray position as the centre of the binding
pocket.
4.8. Biological assays
4.8.1. LEDGF/p75-HIV-1 integrase interaction screening
The AlphaScreen assay was performed as previously describe.43
Reactions were performed in 25 ll ﬁnal volume in 384-well Opti-
well™ microtiter plates (Perkin–Elmer). The reaction buffer con-
tained 25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2,
0.01% (v/v) Tween-20 and 0.1% (w/v) bovine serum albumin.
His6-tagged integrase (300 nM ﬁnal concentration) was incubated
with the compounds at 4 C for 30 min. The compounds were
added in varying concentrations from 1 up to 100 nM. Afterward014), http://dx.doi.org/10.1016/j.bmc.2014.02.012
S. Ferro et al. / Bioorg. Med. Chem. xxx (2014) xxx–xxx 11100 nM of recombinant ﬂag-LEDGF/p75 was added and incubation
was extended by another hour at 4 C. Subsequently, 5 ll of
Ni-chelate-coated acceptor beads and 5 ll of anti-ﬂag donor beads
were added to a ﬁnal concentration of 20 lg/ml of both beads. Pro-
teins and beads were incubated at 30 C for 1 h in order to allow
association to occur. Exposure of the reaction to direct light was
prevented as much as possible and the emission of light from the
acceptor beads was measured in the EnVision plate reader (Per-
kin–Elmer, Benelux) and analyzed using the EnVision manager
software.
4.8.2. Integrase inhibition
To determine the susceptibility of the HIV-1 integrase enzyme
towards our compounds we used enzyme-linked immunosorbent
assays. These assays use an oligonucleotide substrate of which one
oligonucleotide (50-ACTGCTAGAGATTTTCCACACTGACTAAAAGG
GTC-30) is labeledwithbiotin at the30 endand theother oligonucleo-
tide is labeledwith digoxigenin at the 50 end. For the overall integra-
tion assay the second 50-digoxigenin labeled oligonucleotide is
(50-GACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGT-30). For the
Strand Transfer assay the second oligonucleotide lacks GT at the
30end. The integrase enzyme was diluted in 750 mM NaCl, 10 mM
Tris pH 7.6, 10% glycerol and 1 mM b-mercapto ethanol. To perform
the reaction4 ll diluted integrase (corresponding to a concentration
of 1.6 lM) and 4 ll of annealed oligonucleotides (7 nM)were added
in a ﬁnal reaction volume of 40 ll containing 10 lM MgCl2, 5 lM
DTT, 20 lM HEPES pH 7.5, 5% PEG and 15% DMSO. The reaction
was carried out for 1 h at 37 C. Reaction products were denatured
with 30 mMNaOHanddetected by an immunosorbent assay on avi-
din coated plates.44
4.8.3. In vitro anti-HIV and drug susceptibility assays
The inhibitory effect of antiviral drugs on the HIV-induced cyto-
pathic effect (CPE) in human lymphocyte MT-4 cell culture was
determined by the MT-4/MTT-assay.45 This assay is based on the
reduction of the yellow colored 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) by mitochondrial dehydroge-
nase of metabolically active cells to a blue formazan derivative,
which can be measured spectrophotometrically. The 50% cell cul-
ture infective dose (CCID50) of the HIV(IIIB) strain was determined
by titration of the virus stock using MT-4 cells. For the drug-sus-
ceptibility assays, MT-4 cells were infected with 100–300 CCID50
of the virus stock in the presence of ﬁvefold serial dilutions of
the antiviral drugs. The concentration of the various compounds
that achieved 50% protection against the CPE of the different HIV
strains, which is deﬁned as the EC50, was determined. In parallel
the 50% cytotoxic concentration (CC50) was determined.
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